Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.

@article{Colombel2015RandomisedCT,
  title={Randomised clinical trial: deep remission in biologic and immunomodulator na{\"i}ve patients with Crohn's disease - a SONIC post hoc analysis.},
  author={Jean Fred Colombel and Walter Reinisch and Gerassimos Mantzaris and Asher A Kornbluth and Paul Rutgeerts and Kezhen L. Tang and Alessandra Oortwijn and Gideon S. Bevelander and Freddy J. Cornillie and William J Sandborn},
  journal={Alimentary pharmacology & therapeutics},
  year={2015},
  volume={41 8},
  pages={
          734-46
        }
}
BACKGROUND As treatment goals in Crohn's disease (CD) evolve, targets now include clinical remission (CR), mucosal healing (MH) and biological remission [C-reactive protein normalisation (CRPnorm )]. AIMS To evaluate the association of baseline factors and treatment with the achievement of different composite remission parameters at week 26. METHODS This post hoc analysis of the SONIC trial evaluated different composite remission measures at week 26 in a subgroup of patients with Crohn's… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 49 CITATIONS

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Christopher Andrew Lamb, Nicholas A Kennedy, +26 authors A Barney Hawthorne
  • Gut
  • 2019